SARS-CoV-2 vaccination efficacy on hospitalisation and variants

Sacha Rozencwajg; Alice Blet; Antoine Lamer; Thomas Clavier; Osama Abou-Arab; Stéphanie Sigaut; Fanny Bounes; Arthur James; Denis Frasca; Matthieu Boisson; Anaïs Caillard; Aude Carillion; Marc-Olivier Fischer

doi:10.1016/j.accpm.2021.100874

editorial

. 2021 May 1;40(3):100874. doi: 10.1016/j.accpm.2021.100874

SARS-CoV-2 vaccination efficacy on hospitalisation and variants

Sacha Rozencwajg ^a,^b,^⁎, Alice Blet ^c,^d,^e, Antoine Lamer ^f, Thomas Clavier ^g,^h, Osama Abou-Arab ⁱ, Stéphanie Sigaut ^j,^k, Fanny Bounes ^l,^m, Arthur James ⁿ, Denis Frasca ^o,^p, Matthieu Boisson ^o,^q, Anaïs Caillard ^r, Aude Carillion ^n,^h, Marc-Olivier Fischer ^s

^aAP-HP, Bichat University Hospital, DMU PARABOL, Department of Anaesthesiology and Critical Care, Paris, France

^bINSERM UMRS-1166, Institute of Cardiometabolism and Nutrition, Paris, France

^cLariboisière–Saint-Louis Hospitals, Department of Anaesthesiology, Critical Care and Burn Centre, DMU Parabol, AP–HP Nord, University of Paris, Paris, France

^dUniversity of Paris, Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), Paris, France

^eUniversity of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada

^fUniv. Lille, CHU Lille, ULR 2694 - METRICS: Evaluation des Technologies de santé et des Pratiques médicales, F-59000, Lille, France

^gDepartment of Anaesthesiology, Critical Care and Perioperative Medicine, Rouen University Hospital, 1 rue de Germont, 76000 Rouen, France

^hNormandie Univ, UNIROUEN, Inserm U1096, EnVi, Rouen F-76000, France

ⁱUniversity of Amiens-Picardie, Departement of Anaesthesia and Critical Care, Amiens, France

^jAP-HP, Beaujon University Hospital, DMU PARABOL, Department of Anaesthesiology and Critical Care, Clichy, France

^kInserm U1141 NeuroDiderot, Robert Debré Hospital, Paris, France

^lUniversity Hospital of Toulouse, Anaesthesia, Critical Care & Perioperative Medicine, Toulouse, France

^mUniversity of Toulouse III, INSERM U1297, Institute of Cardiovascular and Metabolic Diseases, Toulouse, France

ⁿSorbonne University, GRC 29, AP-HP, DMU DREAM, Department of Anaesthesiology and critical care, Pitié-Salpêtrière Hospital, Paris, France

^oUniversity Hospital of Poitiers, Anaesthesiology, Critical Care and Perioperative Medicine Department, Poitiers, France

^pINSERM UMR-1246, France

^qINSERM U1070, Pharmacology of Antimicrobial Agents, University of Poitiers, France

^rCentre Hospitalier Universitaire La Cavale Blanche Université de Bretagne Ouest, Departement of Anaesthesiology, Critical Care and Perioperative Medicine, Brest, France

^sNormandie Univ, UNICAEN, CHU de Caen Normandie, Service d’Anesthésie Réanimation, 14000 Caen, France

^⁎

Corresponding author. AP-HP, Bichat University Hospital, DMU PARABOL, Department of Anaesthesiology and Critical Care, Paris, France

PMCID: PMC8088124 PMID: 33946037

Abstract

We report data regarding three countries with similar healthcare systems which had three different vaccinal strategies between 1st of January and 10th of April 2021: rapid full vaccination (Israel), rapid first-dose vaccination (United Kingdom) and a delayed vaccination strategy (France).

1. Conflicts of interest

The authors have no conflicts of interest to declare.

References

1.Peiffer-Smadja N, Rozencwajg S, Kherabi Y, et al. COVID-19 vaccines: A race against time. Anaesth Crit Care Pain Med 40:100848. 10.1016/j.accpm.2021.100848. [DOI] [PMC free article] [PubMed]
2.Muik A, Wallisch A-K, Sänger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science 371:1152-1153. 10.1126/science.abg6105. [DOI] [PMC free article] [PubMed]
3.Fergie J, Srivastava A. Immunity to SARS-CoV-2: Lessons Learned. Front Immunol 12:654165. 10.3389/fimmu.2021.654165. [DOI] [PMC free article] [PubMed]
4.Hoffmann M, Arora P, Groß R, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 10.1016/j.cell.2021.03.036. [DOI] [PMC free article] [PubMed]
5.Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. The Lancet 397:1351-1362. 10.1016/S0140-6736(21)00628-0. [DOI] [PMC free article] [PubMed]
6.Edara VV, Norwood C, Floyd K, et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe. 10.1016/j.chom.2021.03.009. [DOI] [PMC free article] [PubMed]
7.Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 10.1016/j.cell.2021.02.037. [DOI] [PMC free article] [PubMed]
8.Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 10.1016/j.cell.2021.03.013. [DOI] [PMC free article] [PubMed]

[bib1010] 1.Peiffer-Smadja N, Rozencwajg S, Kherabi Y, et al. COVID-19 vaccines: A race against time. Anaesth Crit Care Pain Med 40:100848. 10.1016/j.accpm.2021.100848. [DOI] [PMC free article] [PubMed]

[bib0010] 2.Muik A, Wallisch A-K, Sänger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science 371:1152-1153. 10.1126/science.abg6105. [DOI] [PMC free article] [PubMed]

[bib0015] 3.Fergie J, Srivastava A. Immunity to SARS-CoV-2: Lessons Learned. Front Immunol 12:654165. 10.3389/fimmu.2021.654165. [DOI] [PMC free article] [PubMed]

[bib0020] 4.Hoffmann M, Arora P, Groß R, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 10.1016/j.cell.2021.03.036. [DOI] [PMC free article] [PubMed]

[bib0025] 5.Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. The Lancet 397:1351-1362. 10.1016/S0140-6736(21)00628-0. [DOI] [PMC free article] [PubMed]

[bib0030] 6.Edara VV, Norwood C, Floyd K, et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe. 10.1016/j.chom.2021.03.009. [DOI] [PMC free article] [PubMed]

[bib0035] 7.Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 10.1016/j.cell.2021.02.037. [DOI] [PMC free article] [PubMed]

[bib0040] 8.Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 10.1016/j.cell.2021.03.013. [DOI] [PMC free article] [PubMed]

PERMALINK

SARS-CoV-2 vaccination efficacy on hospitalisation and variants

Sacha Rozencwajg

Alice Blet

Antoine Lamer

Thomas Clavier

Osama Abou-Arab

Stéphanie Sigaut

Fanny Bounes

Arthur James

Denis Frasca

Matthieu Boisson

Anaïs Caillard

Aude Carillion

Marc-Olivier Fischer

Abstract

1. Conflicts of interest

References

ACTIONS

PERMALINK

RESOURCES

Cite

Add to Collections

PERMALINK

SARS-CoV-2 vaccination efficacy on hospitalisation and variants

Sacha Rozencwajg

Alice Blet

Antoine Lamer

Thomas Clavier

Osama Abou-Arab

Stéphanie Sigaut

Fanny Bounes

Arthur James

Denis Frasca

Matthieu Boisson

Anaïs Caillard

Aude Carillion

Marc-Olivier Fischer

Abstract

1. Conflicts of interest

References

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases